Human KIR+ CD8+ T cells target pathogenic T cells in Celiac disease and are active in autoimmune diseases and COVID-19

Jing Li(Guangzhou University of Chinese Medicine), Mark M. Davis(Stanford Medicine), Paul J. Utz(Stanford University), Vincent van Unen(Leiden University Medical Center), William H. Robinson(Stanford University), Brad A. Palanski(Vaccine Research Institute of San Diego), Nathan A. Bracey(Stanford University), Kari C. Nadeau(Palo Alto University), James R. Heath(California Institute of Technology), Shin‐Heng Chiou(Stanford University), Chaitan Khosla(Stanford University), Alana M. McSween(Stanford University), Xuhuai Ji(Stanford University), Joy A. Pai(Enzo Life Sciences (United States)), Asbjørn Christophersen(Oslo University Hospital), Jeffrey Dunn(Stanford University), Ansuman T. Satpathy(Palo Alto University), Lucas Kipp(Stanford University), Julie Wilhelmy(Stanford University), Maxim Zaslavsky(Stanford University), Gopal Krishna Dhondalay(Stanford Medicine), Naresha Saligrama(Washington University in St. Louis), Yapeng Su(Collaborative Innovation Center of Chemical Science and Engineering Tianjin), Ludvig M. Sollid(Oslo University Hospital), Kartik Bhamidipati(Translational Therapeutics (United States)), Yueh‐hsiu Chien(Stanford University), Michael J. Sikora(Stanford University), Liang Chen(Tongji University), Jun Li(Sun Yat-sen University), Jing Guo(Tongji University), Lars M. Steinmetz(European Molecular Biology Laboratory), Stephen L. Hauser(University of California, San Francisco), Nielsen Fernandez‐Becker(Stanford University)
The Journal of Immunology
May 1, 2022
Cited by 11


Related Papers